Stoke Therapeutics, Inc. (STOK) · Oct 29, 2026 · Earnings
Miss — GAAP EPS -$1.08 vs. -$0.93 consensus
Stoke Therapeutics earnings beat revenue estimates but missed on EPS as Phase 3 progress remains on track and cash funds operations into early 2028.
Stoke is a clinical-stage biotech funding a pivotal Dravet syndrome program while advancing a second rare-disease asset; the central story remains zorevunersen’s Phase 3 EMPEROR readout in the third quarter of 2027 and a potential U.S. filing afterward. That timeline was already established, so this release mainly updates execution rather than changing the investment case.
The clinical program is progressing, but the filing adds no efficacy signal. Approximately 110 of 162 EMPEROR patients have reached the Week 28 primary-endpoint assessment, about 20 have completed Week 52, and no patients have discontinued treatment. 〔0〕 The FDA meeting also clarified that cognition and behavior will use a four-subdomain Vineland-3 composite, but that is a statistical and regulatory alignment point—not a clinical readout. 〔1〕
The quarter missed on EPS even as collaboration revenue beat expectations. Published Q3 consensus was a $0.93 per-share loss on $8.21 million of revenue; Stoke reported a $1.08 loss and $11.3 million of revenue. The revenue beat is less informative than it looks because it comes from contractual obligations with Acadia and Biogen, while research spending rose sharply to support the pivotal program and launch preparation.
| Q3 2026 | Q3 2025 | Consensus / prior | |
|---|---|---|---|
| Revenue (Financial Results) | $11.3M | $10.6M | $8.21M |
| Diluted EPS (Statements of Operations) | -$1.08 | -$0.65 | -$0.93 |
| R&D expense (Financial Results) | $59.8M | $37.7M | |
| SG&A expense (Financial Results) | $28.7M | $16.0M | |
| Cash, equivalents & securities (Financial Highlights) | $358.8M | $390.9M at Dec. 31, 2025 |
The balance sheet appears sufficient to reach the major milestones, but at a higher spending rate. Stoke says its $358.8 million cash, equivalents and marketable-securities position should fund operations into early 2028. 〔2〕 That covers the planned Phase 3 readout and potential filing window, but the $73.6 million quarterly net loss and heavier operating costs show that the runway depends on continued financing discipline and successful development execution.
STK-002 remains pipeline optionality rather than a new value driver. The ADOA program is moving into its third dose-escalation cohort, with initial safety and efficacy results still expected in the first half of 2027. 〔3〕 This is steady progress, but the release provides no human efficacy result yet.
Bottom line: The core zorevunersen timeline remains intact, but this was not a clean earnings quarter: revenue exceeded expectations while losses and cash consumption ran higher. The business story advances operationally, not clinically, with the decisive evidence still in 2027.
OSPREY data H1 2027; EMPEROR readout Q3 2027
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!